Chautauqua Capital Management, a division of Baird Asset Management, is a boutique investment firm that released its third-quarter 2025 investor letter for the “Baird Chautauqua International and Global Growth Fund”. A copy of the letter can be downloaded here. Global equity markets delivered solid results in the third quarter, driven by the resolution of significant trade conflicts and a shift in U.S. monetary policy toward a more dovish stance. Baird Chautauqua International Growth Fund underperformed the benchmark, MSCI ACWI ex-U.S. Index – ND, in the quarter, driven by stock selection in the information technology, financials, and industrials sectors, which detracted the most from returns. The Baird Chautauqua Global Growth Fund also trailed the benchmark, MSCI ACWI Index – ND, in the quarter as stock selection in the information technology, financials, and industrials sectors detracted the most from returns. In addition, please check the fund’s top five holdings to know its best picks in 2025.
In its third-quarter 2025 investor letter, Baird Chautauqua International and Global Growth Fund highlighted stocks such as BeOne Medicines AG (NASDAQ:ONC). BeOne Medicines AG (NASDAQ:ONC) is an oncology company that focuses on discovering and developing various treatments for cancer patients. The one-month return of BeOne Medicines AG (NASDAQ:ONC) was -7.71%, and its shares gained 64.97% of their value over the last 52 weeks. On December 30, 2025, BeOne Medicines AG (NASDAQ:ONC) stock closed at $304.72 per share, with a market capitalization of $33.72 billion.
Baird Chautauqua International and Global Growth Fund stated the following regarding BeOne Medicines AG (NASDAQ:ONC) in its third quarter 2025 investor letter:
“BeOne Medicines AG (NASDAQ:ONC) reported a strong quarter and raised FY25 guidance, driven by strong momentum from its key growth driver, Brukinsa, which continues to gain market share from its competitors. Management expects positive free cash flow in 2025.”
BeOne Medicines AG (NASDAQ:ONC) is not on our list of 30 Most Popular Stocks Among Hedge Funds. According to our database, 21 hedge fund portfolios held BeOne Medicines AG (NASDAQ:ONC) at the end of the third quarter, compared to 28 in the previous quarter. In Q3 2025, BeOne Medicines AG’s (NASDAQ:ONC) revenue reached $1.4 billion, which represents 41% year-on-year growth. While we acknowledge the potential of BeOne Medicines AG (NASDAQ:ONC) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.